ImmunoPrecise Antibodies Ltd. is a therapeutic antibody discovery company, which engages in the provision of human therapeutic antibody discovery and development services. The firm offers a selection of antibodies, enzymes, enzymes activity assays, arthritis animal products, proteins, deiminated proteins, and hybridoma licensing for research purposes. The company was founded by Robert Beecroft on November 22, 1983 and is headquartered in Victoria, Canada.
相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1983
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- ImmunoPrecise Antibodies sold its Netherlands subsidiary to AVS Bio for $12 million USD, generating $11.7 million in net proceeds to strengthen its balance sheet. - The divestiture allows IPA to concentrate resources on its AI-based LENSai™ platform, which uses HYFT® multi-omics technology to accelerate biologics discovery. - The strategic move reflects IPA's shift toward Software as a Service (SaaS) solutions that unify complex biological data for more efficient drug development processes.
- ImmunoPrecise Antibodies announced that its AI-designed GLP-1 receptor agonist peptides achieved comparable or superior receptor activation to Semaglutide in independent third-party in vitro studies. - Two lead peptide candidates outperformed or matched Semaglutide under controlled assay conditions, with sequences rationally engineered using the company's proprietary HYFT technology for improved stability and peptidase resistance. - The breakthrough validates IPA's LENSai platform and demonstrates that AI can generate functionally validated peptide drugs with potential for rapid expansion into adjacent therapeutic areas. - The company is now considering two preclinical development paths including injectable delivery studies and non-invasive delivery strategies such as transdermal patches and nucleic acid-based delivery systems.
- ImmunoPrecise Antibodies has identified a highly conserved epitope across all four dengue virus serotypes using its proprietary LENSai™ platform powered by patented HYFT® technology. - The discovery represents a major milestone toward developing a universal dengue vaccine by targeting a viral component that remains unchanged despite mutations across all dengue serotypes. - The company plans to extend its AI-driven vaccine design platform to other infectious diseases including HIV, Norovirus, and RSV, with early assessments underway for oncology applications. - The breakthrough was achieved entirely through computational methods, demonstrating the platform's ability to translate complex biological data into actionable vaccine design without laboratory-based inputs.
- ImmunoPrecise Antibodies' LENSai platform matched the performance of x-ray crystallography in epitope mapping using sequence data alone, achieving predictive scores of AUC 0.79-0.89 while reducing turnaround time from weeks to hours. - The AI-powered platform demonstrated true generalization by accurately predicting binding sites on 17 previously unseen antibody-antigen complexes, proving it can work beyond its training data without requiring expensive wet-lab experiments. - This breakthrough addresses critical industry challenges where over 95% of drug candidates fail before reaching the clinic, offering pharmaceutical companies a faster, more cost-effective method for antibody discovery and development.
- India has introduced a ₹5,000 crore research and development fund under the Promotion of Research & Innovation in Pharma MedTech Sector (PRIP) scheme to strengthen capabilities in drug discovery, medical technology, and stem cell therapy. - The initiative aims to address India's R&D investment gap, with domestic companies currently spending only about $3 billion annually compared to $50-60 billion in the US and $15-20 billion in China. - The scheme will support both startups and established pharmaceutical companies through grants and investments, with startups eligible for up to ₹1 crore and larger companies engaged in industrial research potentially securing ₹100-125 crore per project.
- ImmunoPrecise Antibodies has formed a strategic $8-10M partnership with a leading biotechnology company to develop novel cancer therapeutics using AI-driven discovery platforms. - The collaboration will leverage IPA's proprietary B-cell Select™ platform and LENSai™ technology to accelerate the development of Antibody-Drug Conjugates (ADCs) and bispecific antibodies. - The 18-24 month agreement aims to streamline the path from target discovery to preclinical candidate selection, potentially addressing significant unmet medical needs in cancer treatment.
- ImmunoPrecise Antibodies Ltd. and RIBOPRO have established a strategic partnership combining AI-powered antibody discovery with advanced mRNA and lipid nanoparticle technologies. - The collaboration aims to overcome challenges in complex antigen expression, potentially accelerating therapeutic antibody development through improved immune responses and antigen presentation. - By integrating RIBOPRO's mRNA sequence optimization with IPA's B-cell screening and AI-driven workflows, the partnership seeks to create more effective precision therapeutics for complex disease targets.
